Group 1 - Huaying Agriculture and *ST Lvkang previously hit the daily limit down, indicating significant market pressure on these companies [1] - Tianyu Biology experienced a decline of over 8%, reflecting negative sentiment in the sector [1] - Other companies such as Kaichuang International, Biological Shares, Fucheng Shares, and Dahu Shares also followed the downward trend, suggesting a broader industry impact [1]

Core Viewpoint - The animal health sector experienced a significant decline of 4.0% on November 21, with Shunlian Biological leading the drop [1] Market Performance - The Shanghai Composite Index closed at 3834.89, down 2.45% - The Shenzhen Component Index closed at 12538.07, down 3.41% [1] Individual Stock Performance - Shunlian Biological (688098) closed at 9.33, down 5.85% with a trading volume of 58,100 shares and a turnover of 55.30 million yuan - Huisheng Biological (300871) closed at 19.33, down 5.71% with a trading volume of 65,400 shares and a turnover of 130 million yuan - Yongshun Biological (920729) closed at 8.81, down 5.47% with a trading volume of 23,700 shares and a turnover of 21.71 million yuan - *ST Green Health (002868) closed at 41.88, down 4.99% with a trading volume of 5,569 shares and a turnover of 23.32 million yuan - Biological Shares (600201) closed at 11.76, down 4.85% with a trading volume of 491,800 shares [1] Capital Flow Analysis - The animal health sector saw a net outflow of 128 million yuan from institutional investors, while retail investors had a net inflow of 87.82 million yuan [1] - The following stocks had notable capital flows: - Shunlian Biological: net outflow of 11.71 million yuan from institutional investors [2] - *ST Green Health: net outflow of 6.34 million yuan from institutional investors, but a net inflow of 990,000 yuan from retail investors [2] - Huisheng Biological: net outflow of 8.69 million yuan from institutional investors, with a net inflow of 432,630 yuan from retail investors [2]

Group 1 - The report tracks stocks, industries, and sectors that are reaching new highs, indicating market trends and hotspots [1][4][24] - As of November 21, 2025, the distance to the 250-day new high for major indices is as follows: Shanghai Composite Index 4.83%, Shenzhen Component Index 8.65%, CSI 300 6.20%, CSI 500 9.69%, CSI 1000 7.59%, CSI 2000 7.40%, ChiNext Index 12.16%, and STAR 50 Index 16.45% [5][24] - Among the CITIC primary industry indices, the sectors closest to their 250-day new highs include petroleum and petrochemicals, textiles and apparel, basic chemicals, home appliances, and steel [8][24] Group 2 - A total of 1,127 stocks reached a 250-day new high in the past 20 trading days, with the highest number of new highs in the basic chemicals, machinery, and power equipment and new energy sectors [2][13][24] - The highest proportion of new high stocks is found in the textiles and apparel, coal, and non-ferrous metals sectors, with respective proportions of 41.41%, 38.89%, and 38.71% [13][24] - The cyclical and manufacturing sectors had the most new high stocks this week, with 364 and 315 stocks respectively [15][24] Group 3 - The report identifies 15 stocks that have shown stable new highs, including Heertai, Sry New Materials, and Cangge Mining, with the manufacturing and cyclical sectors contributing the most stocks [3][20][25] - The construction industry had the highest number of new highs within the manufacturing sector, while the non-ferrous metals industry led in the cyclical sector [20][25]

Core Viewpoint - Green Leaf Pharmaceutical (02186) announced the issuance of exchangeable preferred shares worth $150 million, which will be exchanged for shares of Boan Biologics (600201) under specific terms outlined in the subscription agreement [1] Group 1: Financial Details - The total subscription price for the exchangeable preferred shares is $150 million [1] - The proceeds from the subscription will be used for general working capital purposes of the group [1] Group 2: Strategic Implications - The issuance of exchangeable preferred shares provides the company with immediate cash funding while maintaining strategic flexibility [1] - The exchange mechanism allows the company to monetize its investment in Boan Biologics over a longer period at a price above the current market level, which is expected to yield better results compared to bulk disposals at discounted prices [1] Group 3: Investor Information - The subscriber is a company registered under the laws of the Cayman Islands, with RRJ Capital Master Fund IV, L.P. as its direct shareholder, holding 100% of the issued share capital [1] - The main business of the subscriber is investment holding activities [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688739 证券简称：成大生物 公告编号：2025-055 辽宁成大生物股份有限公司 关于召开2025年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2025年11月28日（星期五）上午 9:00-10:00 会议召开地点：上海证券交易所上证路演中心 （网址：http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于2025年11月21日（星期五）至11月27日（星期四）16:00前登录上证路演中心网站首页点 击"提问预征集"栏目或通过公司邮箱lncdsw@cdbio.cn进行提问。公司将在说明会上对投资者普遍关注 的问题进行回答。 辽宁成大生物股份有限公司（以下简称"公司"）于2025年10月30日发布公司2025年第三季度报告，为便 于广大投资者更全面深入地了解公司2025年第三季度的经营成果、财务状况，公司计划于2025年11月28 日上午 9:00- ...

Core Viewpoint - The stock of Jinyu Biological Technology Co., Ltd. has shown significant growth this year, with an 81.11% increase in share price, indicating strong market performance and investor interest [1][2]. Company Overview - Jinyu Biological Technology Co., Ltd. is located in Hohhot, Inner Mongolia, and was established on March 13, 1993, with its stock listed on January 15, 1999. The company primarily engages in the research, production, and sales of veterinary biological products [1]. - The main revenue composition includes 94.42% from biopharmaceuticals, 3.18% from other income, and 2.40% from supplementary sources [1]. Financial Performance - For the period from January to September 2025, the company achieved an operating income of 1.042 billion yuan, representing a year-on-year growth of 7.38%. However, the net profit attributable to shareholders decreased by 4.85% to 161 million yuan [2]. - The company has distributed a total of 2.219 billion yuan in dividends since its A-share listing, with 189 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 10.70% to 49,000, while the average circulating shares per person increased by 11.12% to 22,673 shares [2]. - Notable institutional shareholders include Guotai Zhongxin Livestock Breeding ETF, which holds 25.0398 million shares, and Hong Kong Central Clearing Limited, holding 21.1968 million shares, both showing increases in their holdings [3].

Core Viewpoint - The animal health sector experienced a slight decline of 0.31% on November 19, with Xianfeng Holdings leading the losses, while the Shanghai Composite Index rose by 0.18% to close at 3946.74 [1]. Group 1: Market Performance - The animal health sector's individual stock performance varied, with notable gainers including Qudongli (up 3.98% to 10.71) and ST Lvkang (up 3.80% to 46.40) [1]. - Conversely, several stocks faced declines, such as Jinhai Biological (down 0.96% to 6.19) and Shunlian Biological (down 1.08% to 10.12) [1][2]. Group 2: Trading Volume and Capital Flow - The total trading volume for the animal health sector was significant, with Qudongli achieving a volume of 34,000 hands and a transaction value of approximately 35.9 million yuan [1]. - The sector saw a net outflow of 49.13 million yuan from institutional investors, while retail investors contributed a net inflow of 548.09 million yuan [2]. Group 3: Individual Stock Capital Flow - Among individual stocks, Shengong Holdings experienced a net outflow of 31.56 million yuan from retail investors, while Biotech Holdings saw a net inflow of 555.72 million yuan from retail investors [3]. - The stock with the highest net inflow from retail investors was Biotech Holdings, with 555.72 million yuan, while the largest net outflow was from Yongshun Biological, totaling 408.61 million yuan [3].

Core Insights - The swine industry is experiencing significant losses, with the average selling price of live pigs dropping to 11.56 yuan/kg, leading to a loss of 71.95 yuan per head for self-bred pigs [1] - Analysts suggest that the current oversupply and weak demand may result in a "non-peak" season for pork prices in Q4, indicating potential investment opportunities in the sector [1] - The industry is expected to undergo capacity reduction, which may lead to an upward adjustment of pork price levels by 2026, benefiting low-cost producers [1] Group 1: Market Performance - As of November 18, 2025, the China Livestock Breeding Index (930707) showed mixed performance among its constituent stocks, with Muyuan Foods (002714) leading with a 0.43% increase [1] - The Livestock ETF (516760) was quoted at 0.7 yuan [1] - The top ten weighted stocks in the index accounted for 65.58% of the total index weight, indicating a concentration in a few key players [2] Group 2: Stock Performance - The stock performance of key companies includes: - Muyuan Foods (002714): +0.43%, weight 11.37% - Haida Group (002311): +0.34%, weight 9.52% - Biological Shares (600201): +0.25%, weight 3.91% - Other notable declines include New Hope (000876): -1.01% and Tian康 Biological (002100): -1.96% [4]

Core Points - The chairman of Baolingbao Biotech Co., Ltd., Mr. Dai Jue, has resigned due to personal reasons, effective immediately upon submission of his resignation report [1][2] - Mr. Dai Jue will continue to serve as a director for the company's wholly-owned subsidiaries, BLB International Development (Singapore) PTE. LTD. and BLB Bio-Tech USA INC [1] - The resignation will not affect the minimum number of board members or the normal operation of the board and the company [2] Company Information - Mr. Dai Jue holds 29,508,653 shares of the company through Beijing Yongyu Investment Management Co., Ltd., representing 7.75% of the total share capital, and is one of the actual controllers of the company [2] - The board expressed gratitude for Mr. Dai Jue's contributions to the company's strategic development and stable operations during his tenure [2]

Core Viewpoint - The company, Jinyu Biotechnology Co., Ltd., is set to hold a performance briefing for the third quarter of 2025 on November 26, 2025, to discuss its operational results and financial status with investors [2][3]. Group 1: Meeting Details - The performance briefing will take place on November 26, 2025, from 15:00 to 17:00 [5]. - The location for the meeting is the Shanghai Stock Exchange Roadshow Center, accessible via the website http://roadshow.sseinfo.com/ [5]. - The meeting will be conducted through video live streaming and online interaction [3][5]. Group 2: Investor Participation - Investors can submit questions for the briefing from November 19, 2025, to November 25, 2025, before 16:00, either through the Roadshow Center website or via the company's email [6]. - The company will address commonly asked questions during the briefing [3][6]. Group 3: Company Representatives - Key representatives attending the meeting include Chairman Zhang Chongyu, CFO Li Kai, and Vice Chairman and President Zhang Jing [4][5].